DK2043671T3 - Peptid og sammensætning deraf til anvendelse ved behandling af slagtilfælde med feber - Google Patents
Peptid og sammensætning deraf til anvendelse ved behandling af slagtilfælde med feber Download PDFInfo
- Publication number
- DK2043671T3 DK2043671T3 DK07796769.3T DK07796769T DK2043671T3 DK 2043671 T3 DK2043671 T3 DK 2043671T3 DK 07796769 T DK07796769 T DK 07796769T DK 2043671 T3 DK2043671 T3 DK 2043671T3
- Authority
- DK
- Denmark
- Prior art keywords
- peptid
- february
- cases
- treatment
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83018906P | 2006-07-11 | 2006-07-11 | |
| US83357206P | 2006-07-26 | 2006-07-26 | |
| PCT/US2007/015747 WO2008008348A2 (en) | 2006-07-11 | 2007-07-10 | Method and compositions for treating stroke with fever |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2043671T3 true DK2043671T3 (da) | 2020-06-15 |
Family
ID=38923841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07796769.3T DK2043671T3 (da) | 2006-07-11 | 2007-07-10 | Peptid og sammensætning deraf til anvendelse ved behandling af slagtilfælde med feber |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8685925B2 (da) |
| EP (1) | EP2043671B1 (da) |
| JP (2) | JP5746468B2 (da) |
| CA (1) | CA2657665C (da) |
| DK (1) | DK2043671T3 (da) |
| ES (1) | ES2804424T3 (da) |
| WO (1) | WO2008008348A2 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7510824B2 (en) * | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| US7595297B2 (en) * | 1999-06-02 | 2009-09-29 | Michael Tymianski | Method of reducing injury to mammalian cells |
| US8933013B2 (en) * | 2007-12-05 | 2015-01-13 | Nono Inc. | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| WO2010004003A2 (en) * | 2008-07-09 | 2010-01-14 | University Of Copenhagen | Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction |
| US8940699B2 (en) * | 2009-06-10 | 2015-01-27 | Nono Inc. | Model systems and treatment regimes for treatment of neurological disease |
| CN103533949B (zh) * | 2011-05-13 | 2015-11-25 | 哥本哈根大学 | 作为缺血性脑损伤的有效神经保护剂并用于治疗疼痛的psd-95的高亲和力的二聚抑制剂 |
| US9139615B2 (en) | 2011-05-13 | 2015-09-22 | University Of Copenhagen | High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain |
| KR102296106B1 (ko) | 2011-06-24 | 2021-08-30 | 노노 인코포레이티드 | 허혈에 대한 psd-95 억제제와의 조합 요법 |
| US9241970B2 (en) | 2011-12-13 | 2016-01-26 | Nono Inc. | Therapy for subarachnoid hemorrhage and ischemia |
| US9680916B2 (en) | 2013-08-01 | 2017-06-13 | Flowtraq, Inc. | Methods and systems for distribution and retrieval of network traffic records |
| JP6958913B2 (ja) | 2015-11-06 | 2021-11-02 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ | 心停止の処置のためのペプチドおよび方法 |
| EP3650460A4 (en) * | 2017-07-05 | 2021-03-17 | Biocells (Beijing) Biotech Co., Ltd. | PHARMACEUTICAL SALT OF A POLYPEPTID AND ITS USES |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE168416T1 (de) | 1989-10-05 | 1998-08-15 | Optein Inc | Zellfreie synthese und isolierung von genen und polypeptiden |
| US5747334A (en) | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US7510824B2 (en) * | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| EP1578365A4 (en) * | 2002-11-14 | 2009-09-23 | Arbor Vita Corp | MOLECULAR INTERACTIONS IN NEURONS |
| US7858322B2 (en) * | 2003-12-23 | 2010-12-28 | Nono, Inc. | Method of determining inhibition of binding to TRPM7 protein |
| EP1884521A1 (en) * | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| EP2120987B1 (en) | 2007-03-02 | 2014-01-15 | NoNO Inc. | Treating stroke and other diseases without inhibiting n-type calcium channels |
| US8080518B2 (en) * | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
-
2007
- 2007-07-10 JP JP2009519493A patent/JP5746468B2/ja active Active
- 2007-07-10 US US12/307,581 patent/US8685925B2/en active Active
- 2007-07-10 DK DK07796769.3T patent/DK2043671T3/da active
- 2007-07-10 CA CA2657665A patent/CA2657665C/en active Active
- 2007-07-10 WO PCT/US2007/015747 patent/WO2008008348A2/en active Application Filing
- 2007-07-10 ES ES07796769T patent/ES2804424T3/es active Active
- 2007-07-10 EP EP07796769.3A patent/EP2043671B1/en active Active
-
2013
- 2013-02-04 JP JP2013019300A patent/JP6088272B2/ja active Active
-
2014
- 2014-02-07 US US14/175,861 patent/US20140323406A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2804424T3 (es) | 2021-02-08 |
| US20140323406A1 (en) | 2014-10-30 |
| EP2043671A4 (en) | 2010-09-15 |
| US8685925B2 (en) | 2014-04-01 |
| EP2043671B1 (en) | 2020-05-20 |
| CA2657665A1 (en) | 2008-01-17 |
| WO2008008348A3 (en) | 2008-06-12 |
| US20120208764A1 (en) | 2012-08-16 |
| WO2008008348A2 (en) | 2008-01-17 |
| JP2013151495A (ja) | 2013-08-08 |
| CA2657665C (en) | 2015-06-02 |
| JP6088272B2 (ja) | 2017-03-01 |
| JP2009544585A (ja) | 2009-12-17 |
| EP2043671A2 (en) | 2009-04-08 |
| JP5746468B2 (ja) | 2015-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2043671T3 (da) | Peptid og sammensætning deraf til anvendelse ved behandling af slagtilfælde med feber | |
| DK2322221T3 (da) | Farmaceutisk sammensætning til behandling og forebyggelse af cancer | |
| DK1862158T3 (da) | Farmaceutisk sammensætning til behandling af depression og fremgangsmåde til fremstilling deraf | |
| DK2653873T3 (da) | Sammensætninger og anvendelser til behandling af multipel sklerose | |
| DK2463283T3 (da) | Kondenserede heterocykliske phenylamidoforbindelser til forebyggelse og behandling af glucokinase-medierede sygdomme | |
| DK2101819T3 (da) | Fremgangsmåder, sammensætninger og kits til behandling af smerte og pruritis | |
| DK2155188T3 (da) | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft | |
| DK1781256T3 (da) | Phospholipid-gel-sammensætning til lægemiddelafgivelse og fremgangsmåder til behandling af sygdomme ved hjælp af samme | |
| DK1888033T3 (da) | Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme | |
| DK2001611T3 (da) | Fremgangsmåde og sammensætning til oprensning af jord | |
| DK2131856T3 (da) | Sammensætninger og fremgangsmåder til forebyggelsen og behandlingen af autoimmune tilstande | |
| DK1877232T3 (da) | Fremgangsmåde til behandling af træoverflader | |
| DK2032156T3 (da) | Sammensætninger og fremgangsmåder til levering af oxygen | |
| DK2029746T3 (da) | Sammensætninger og fremgangsmåder til siRNA-hæmning af angiogenese | |
| DK1858864T3 (da) | Stabiliserede sammensætninger af flygtige alkyleringsmidler og fremgangsmåder til anvendelse deraf | |
| DK3081215T3 (da) | Sammensætninger og fremgangsmåder til langvarig frigørelse af beta-alanin | |
| DK2185164T3 (da) | Sammensætning og terapeutisk antitumorvaccine | |
| DK2124999T3 (da) | Activin-actrii antagonister og anvendelser til behandling af anæmi | |
| DK3263589T5 (da) | Peptidsekvenser og sammensætninger | |
| DK1948695T3 (da) | Immunogene sammensætninger og fremgangsmåder til andvendelse | |
| DK1771201T3 (da) | Sammensætninger og fremgangsmåder til behandling eller forebyggelse af oxalat-relateret sygdom | |
| DK2069467T3 (da) | Adskillende sammensætninger og fremgangsmåder til anvendelse | |
| DK2063881T3 (da) | Sammensætning og fremgangsmåde til virksom og sikker administration af halopyruvat til behandlingen af cancer | |
| DK2099796T3 (da) | Aza-indolyl-forbindelser og fremgangsmåder for anvendelse | |
| DK2114447T3 (da) | Forebyggelse og behandling af subkliniks pcvd |